Strategic Channel Sales Partnership Established with AsedaScience's Predictive ML-Guided Toxicity and Visualization Platform
Hesperos and AsedaSciences are pleased to announce the establishment of a strategic channel sales and marketing partnership offering biopharma, cosmetics, food and chemical clients a powerful combination of human-based, in silico and in vitro screening, testing, analysis and data visualization capabilities to further accelerate product development.
Highlights at a Glance
AsedaSciences 3RnD® Platform
A cloud-based SaaS solution that integrates high-content human cell–based testing, ML-guided toxicity risk predictions, and advanced data visualization, 3RnD can help teams design, select, and advance safer chemicals earlier in the R&D process.
Strategic Partnership
This partnership combines the power of Aseda’s extensive 3RnD chemical and cellular toxicity screening data surfaced within its intuitive, actionable, data analytics visualization platform with Hesperos’ Human-on-a-Chip® microphysiological single- and multi-organ system preclinical models that replicate complex, human physiology to improve the predictiveness of preclinical testing and bring new, safe and effective treatments to patients more quickly.
Faster, More Informed Decisions
Clients can leverage data visualization tools within 3RnD that are simple to use and intuitive to interpret, enabling faster, more informed decision-making. Results from Hesperos studies can be compared to data from thousands of previously evaluated compounds, providing rich biological and contextual insights.
Clients can seamlessly move from discovery to Hesperos’ IND-enabling human-based organ system models, combining early screening data with advanced preclinical insights for better informed, more predictive safety, efficacy, and PK/PD results.
Brad Calvin, CEO, AsedaSciences
More details coming soon!
About AsedaSciences
AsedaSciences’ platform provides integrated non-animal screening methods, machine learning, and cloud-based data analysis and visualization for earlier prediction of toxicity risk to support safer compound design across the chemical-producing industries. Through its innovative, cloud-based, AI-driven 3RnD platform, AsedaSciences empowers scientists to rapidly understand the relationship between chemical structures and their biological effects to support the selection of safer compounds. For more information about AsedaSciences and the 3RnD platform, please visit www.asedasciences.com.
Discover how we can advance your pipeline faster and more efficiently
Explore Other Hesperos News
Announcing Strategic Channel Sales Partnership with AsedaSciences for Better Predictive, More Efficient, & Lower Cost Drug/Product Development
Hesperos and AsedaSciences announce a strategic channel sales partnership combining Human-on-a-Chip® and AI-driven 3RnD® to advance safer, more efficient drug and chemical development.
Human-on-a-Chip® Advancements: Industry Recognition and New Research Published
Hesperos’ Human-on-a-Chip® technology earns recognition in a Nature Lab Animal article highlighting advancements in human-relevant, new alternative methods (NAMs) models and publishes new research advancing its sarcopenia-on-a-chip system.
Hesperos and Oriental Yeast Co., Ltd. Announce Strategic Partnership to Expand Human-on-a-Chip® Services Across Asia
Hesperos and Oriental Yeast Co. form a strategic partnership to expand access to Human-on-a-Chip® services across Asia, accelerating safer, more effective preclinical drug development.